Q1 2025 Earnings Call Transcript February 13, 2025 Veru Inc. beats earnings expectations. Reported EPS is $-0.06, ...

There are no studies documenting the percentage of doctors taking the drugs. But physicians “are a good litmus test for drugs ...

More than 40 percent of Qataris are clinically obese, due to sedentary lifestyles, genetic factors, and cultural preferences ...

Discover how small biotechs are innovating in the weight loss therapy market with new treatments targeting unique mechanisms ...

Palatin Technologies, Inc. (AMEX: PTN) Q2 2025 Earnings Call Transcript February 13, 2025 ...

Debate over childhood obesity treatments: weight-loss drugs vs. lifestyle changes, with concerns about long-term effects.

Q1 2025 Management View Veru highlighted its transformation into a late clinical-stage biopharmaceutical company focusing on cardiometabolic and inflammatory diseases, with major developments in ...

Company reported positive Phase 2b QUALITY study topline results for enobosarm + semaglutide (Wegovy®) with study meeting prespecified primary endpoint of preservation of lean mass as well as greater ...

Hershey's current stock decline is due to high cocoa prices, but historical trends suggest recovery once prices normalize.

State lawmakers have introduced bills to limit SNAP benefits, change vaccine policies and ban fluoride in public water.

Since expenditures are heavily skewed, the top 5 percent of patients by cost contribute a disproportionate amount to the mean ...